SCHEMBL2785435

SCHEMBL2785435

N#Cc1ccc(N=C(N)NCc2ccccc2Cl)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ VNN1 O95497 1/20 0.42
▸ AADAT Q8N5Z0 1/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ P2RX7 Q99572 1/20 0.37
▸ AURKA O14965 1/20 0.36
▸ RPS6KB1 P23443 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ FLT3 P36888 1/20 0.35
▸ IRAK4 Q9NWZ3 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2781731 0.82 ADRA2A (0.54) NPC1RAB9ACYP1A2CYP3A4CYP2C19
SCHEMBL2782802 0.82 NPC1 (0.42) NPC1RAB9ACYP1A2CYP3A4CYP2C19
SCHEMBL2780903 0.80 VNN1 (0.41) VNN1AADATNPC1RAB9ACYP1A2
SCHEMBL2780684 0.80 PLAU (0.39) CYP1A2CYP3A4CYP2C19MAPK1ALDH1A1
SCHEMBL2785430 0.73 NPC1 (0.43) VNN1AADATNPC1RAB9ACYP1A2
SCHEMBL4681736 0.73 NPC1 (0.51) NPC1RAB9ACYP3A4CYP2C19SMN1; SMN2
SCHEMBL4681732 0.73 NPC1 (0.51) NPC1RAB9ACYP3A4CYP2C19SMN1; SMN2
SCHEMBL2444272 0.68 KMT2A (0.44) NPC1RAB9ACYP1A2CYP3A4CYP2C19
SCHEMBL2779762 0.68 ADRA2A (0.55) NPC1RAB9AADRA2AADRA2BADRA2C
Acetic Acid SCHEMBL2780902 0.68 VNN1 (0.45) VNN1AADATNPC1RAB9ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296697-B2 Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors ABBOTT LABORATORIES (US) 2016-03-29 — — US claimed
US-9296697-B2 Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors ABBOTT LABORATORIES (US) 2016-03-29 — — US disclosed
US-20100184787-A1 Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2010-07-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184787-A1 Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors HTR5A, HTR2C, HTR1E VNN1 4002/4885AADAT 826/4885NPC1 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback